
    
      This is an open-label, multi-center Phase Ib study of safety, PK of APG-2575 as a single
      agent or in combination with HHT or AZA in relapsed/refractory AML patients.

      This study consists of three stages: The first stage is the APG-2575 single agent escalation
      study. The second stage is the APG-2575 combined with HHT/AZA escalation study. The third
      stage is the MTD/RP2D expansion cohort study of the combination regimen.
    
  